Ipsen (FR:IPN) has released an update.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Ipsen’s Bylvay® demonstrates promising long-term efficacy and safety in treating rare cholestatic liver diseases, including PFIC and ALGS, with significant improvements in symptoms such as itch severity and serum bile acid levels over 72 weeks. The treatment has also shown benefits in patient growth and sleep quality, with most adverse events reported as mild or moderate. Ipsen aims to lead advancements in managing these challenging conditions.
For further insights into FR:IPN stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Super Micro Stock Soars 40% on Hiring New Auditor and Averting Delisting
- ‘Stay Away for Now,’ Says Top Investor About Palantir Stock
- ‘Too Late to Jump In,’ Says Ladenburg About SoundHound AI Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
